Nonviral delivery of cancer genetic vaccines.
The potential use of genetic vaccines to address numerous diseases including cancer is promising, but currently unrealized. Here, we review advances in the nonviral delivery of antigen-encoded plasmid DNA for the purpose of treating cancer through the human immune system, as this disease has drawn the most attention in this field to date. Brief overviews of dendritic cell immunobiology and the mechanism of immune activation through genetic vaccines set the stage for the desirability of delivery technology. Several promising nonviral delivery techniques are discussed along with a mention of targeting strategies aimed at improving the potency of vaccine formulations. Implications for the future of genetic vaccines are also presented.
Department of Chemical Engineering and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02142, USA.
Steven R
SR
Little
Robert
R
Langer
D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D019496:Cancer Vaccines; D019444:Vaccines, DNA